Alain Thibault

Alain Thibault has extensive work experience in the pharmaceutical and biotech industry. Alain currently holds the position of Chief Medical Officer at EverImmune since July 2022. Prior to this, they served as the Therapeutic Area Head - Oncology at Annexin Pharmaceuticals AB (publ) starting from January 2023. Alain was also a Senior Advisor at TVM Capital Life Science since July 2021. Alain Thibault has held various roles throughout their career, including Chief Medical Officer at iTeos Therapeutics, Menarini Silicon Biosystems, and ArGEN-X. Alain also served as the Vice-president Oncology at Regeneron Pharmaceuticals and Senior Medical Director at Johnson & Johnson. Alain Thibault started their career as a Director at Roche.

Alain Thibault started their education journey in 1981 at McGill University, where they pursued a degree in Medicine. Alain successfully completed their MD degree and concluded their studies in 1986. Following their medical degree, in 1991, Alain Thibault enrolled at the National Cancer Institute. There, they obtained a degree as a Visiting Associate in Clinical Pharmacology, concluding their studies in 1995.